The company uses polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury.

The data showed evidence of efficacy with respect to increased neural survival, decreased lesion size and decreased scarring.

The pilot study enrolling 10 humans patients tested a biomaterial scaffold implant without drugs or cells and is the subject of a proposed in acute spinal cord injury, which the company hopes to begin next year.

InVivo Therapeutics medical director Jonathan Slotkin said these data provide further encouragement as they work with the FDA on their recently submitted application.